Atea Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Atea Pharmaceuticals, Inc. (AVIR) had Debt Securities, Available-for-sale, Unrealized Loss Position of $16.16 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2024-11-07
- 2024-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $16.16M.
- 2024-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $235.85M.
- 2024-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $261.06M.
- 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $178.00M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2024-09-30 | $16.16M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $235.85M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $261.06M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $178.00M 10-K · filed 2024-02-28 |
| 2023-09-30 | $272.30M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $201.95M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $152.79M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $143.22M 10-K · filed 2024-02-28 |
| 2022-09-30 | $157.50M 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |